Overview
BioIVT is a prominent global supplier in the biotechnology and healthcare sectors, concentrating on high-quality biological and in vitro products and services for pharmaceutical, biotechnology, and healthcare organizations. With its headquarters in Westbury, United States, BioIVT provides personalized biospecimen solutions that facilitate advancements in life sciences, drug discovery, and diagnostic development. Originally known as BioreclamationIVT, the company is known for its comprehensive clinical data and donor samples, supporting precision medicine research.
Products and Services
BioIVT offers an extensive portfolio of human and animal biospecimens, which can be customized to meet specific client needs. Their key product categories include:
- Biofluids: Blood-derived and other biofluids used in various research applications.
- Cell Products: A wide array applicable to research purposes.
- Media/Reagents/Kits: Essential materials for laboratory procedures.
- Molecular Products: Including DNA/RNA and related biocomponents for molecular biology needs.
- Subcellular Fractions & Recombinant Enzymes: Tailored for biochemical research purposes.
- Tissues: Extensive selection provided for histological research studies.
BioIVT also delivers specialized preclinical research services, including in vitro and in vivo ADME (absorption, distribution, metabolism, and excretion) programs, bioanalysis, and consulting in ADME processes. Adding to their initiative, BioIVT has introduced a Center for NeuroExcellence to support neuro-related biospecimen solutions.
Strategic Acquisitions and Developments
BioIVT pursues strategic acquisitions to enhance service capabilities and expand their market presence. Notable acquisitions include:
- ZenBio Inc., which bolstered its drug discovery and cosmetics applications offerings.
- XenoTech, augmenting BioIVT’s prowess in in vitro ADME services.
- Asterand Bioscience acquired in 2017, which enhanced BioIVT’s provision of high-quality, clinically validated human tissue solutions, with a focus on oncology.
In 2024, together with Germfree, BioIVT launched a new cleanroom manufacturing space to emphasize its focus on cell and gene therapy development.
Leadership
The leadership team at BioIVT is spearheaded by Dr. Richard Haigh, who transitioned from the role of Chief Operating Officer in May 2022 to Chief Executive Officer in August 2022. Dr. Haigh possesses over 27 years of experience in life sciences and diagnostics, having formerly held senior positions at Thermo Fisher Scientific and Quanterix. Key team members include Jennifer Murphy, Senior Vice President of Global Commercial Operations, and Matt Chorley, Vice President of Global Quality, who are instrumental in steering the company’s strategic initiatives.
Market Position and Competitor Landscape
BioIVT is positioned as an industry leader in biospecimen contract research services, providing control and disease state samples crucial for pharmaceutical and biotechnological research. They foster their reputation by delivering innovative solutions that advance medical discoveries through more intelligent scientific methods. Competitors within their landscape include:
- Bay BioSciences, BioLife Solutions, ABS Inc, Illumina, Abcam, Discovery Life Sciences, SeraCare Life Sciences, AMSBIO, Asterand Bioscience, ProMedDx, and Protein Biotechnologies, all offering substantial market presence and critical competition in related domains.
The biospecimen contract research services market, where BioIVT stands alongside major players such as BioChain Institute and Boca Biolistics, is projected to reach a valuation of USD 11.70 billion by 2031.
Recent Financials and Employee Information
BioIVT has secured a total of $45 million in funding, with its latest funding round closing on July 16, 2013, as debt financing. The company generates an annual revenue of approximately USD 69.3 million, supported by a workforce of around 447 employees. BioIVT continues to enhance its financial positioning through strategic investments and acquisitions.
Branding and Market Strategy
BioIVT is recognized for its control and disease state samples alongside a wide array of product offerings that ensure quality and attentive customer service. By persistently expanding its capabilities and product portfolio, BioIVT maintains a competitive edge in the rapidly evolving biotechnology and healthcare industries, supporting global partners in achieving medical breakthroughs that extend and improve life quality.
